Clinical tolerance and toxicity of intravenous baclofen: A pilot study in a canine model

Journal of Pediatric Rehabilitation Medicine

Volumn 4, Issue 2, 2011, Pages 89-98

  Krach, Linda E ^a,c   Kriel, Robert L ^a,b,c   Patterson, Edward E ^b   Scherkenbach, Lisa A ^c   Coles And, Lisa D ^b,c   Cloyd, James C ^b,c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Baclofen; dogs; muscle spasticity; pharmacokinetic

Indexed keywords

BACLOFEN;

ANIMAL EXPERIMENT; ARTICLE; ATAXIA; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; NONHUMAN; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEDATION; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANIMALS; BACLOFEN; BIOLOGICAL AVAILABILITY; DOGS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MODELS, ANIMAL; MUSCLE RELAXANTS, CENTRAL; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 80155153043     PISSN: 18745393     EISSN: 18758894     Source Type: Journal    
DOI: 10.3233/PRM-2011-0160     Document Type: Article

References (33)

1. D. J. Matthews and P. Wilson, Cerebral Palsy, in: Pediatric Rehabilitation: Third Edition Philadelphia: Hanley & Belfus, G. E. Mohar and M. A. Alexander, eds, 1999, pp. 193-217.
2. G. M. Sawa and D. W. Paty, The use of baclofen in treatment of spasticity in multiple sclerosis, Can J Neurol Sci 6(3) (1979), 351-354.
3. A. I. Korenkov, W. R. Niendorf, N. Darwish, E. Glaeser and M. R. Gaab, Continuous intrathecal infusion of baclofen in patients with spasticity caused by spinal cord injuries, Neurosurg Rev 25(2002), 228-230.
4. J. M. Meythaler, M. J. DeVivo and M. Hadley, Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury, Arch Phys Med Rehabil 77(1996), 461-466.
5. A. L. Albright, Spastic Cerebral Palsy: Approaches to Drug Treatment, CNS Drugs 4(1) (1995), 17-27.
6. R. J. Coffey, T. S. Edgar, G. E. Francisco, V. Graziani, J. M. Meythaler, P. M. Ridgely et al., Abrupt Withdrawal From Intrathecal Baclofen: Recognition and Management of a Potentially Life-Threatening Syndrome, Arch Phys Med Rehabil 83(2002), 735-741.
7. J. M. Meythaler, J. F. Roper and R. C. Brunner, Cyproheptadine for Intrathecal Baclofen Withdrawal, Arch Phys Med Rehabil 84(2003), 638-642.
8. L. B. Green and V. S. Nelson, Death After Acute Withdrawal of Intrathecal Baclofen: Case Report and Literature Review, Arch Phys Med Rehabil 80(1999), 1600-1604.
9. J. C. Ross, A. M. Cook, G. L. Stewart and B. G. Fahy, Acute Intrathecal Baclofen Withdrawal: A Brief Review of Treatment Options, Neurocrit Care 14(2011), 103-108.
10. M. L. Salazar and L. S. Eiland, Intrathecal Baclofen Withdrawal Resembling Serotonin Syndrome in an Adolescent Boy with Cerebral Palsy, Pediatr Emerg Care 24(10) (2008), 691-693.
11. M. R. Turner and N. Gainsborough, Neuroleptic malignant-like syndrome after abrupt withdrawal of baclofen, J Psychopharmacol 12(1) (2001), 61-63.
12. K. Kolaski and L. R. Logan, A review of the complications of intrathecal baclofen in patients with cerebral palsy, NeuroRehabil 22(5) (2007), 383-395.
13. R. L. Kriel, L. E. Krach, D. S. Hoff, M. E. Gormley, Jr. and C. Jones-Saete, Failure of Absorption of Baclofen after Rectal Administration, Pediatr Neurol 16(1997), 351-352.
14. C. R. Hansen, J. L. Gooch and T. Such-Neibar, Prolonged, Severe Intrathecal Baclofen Withdrawal Syndrome: A Case Report, Arch Phys Med Rehabil 88(2007), 1468-1471.
15. M. Cruikschank and P. Eunson, Intravenous diazepam infusion in the management of planned intrathecal baclofen withdrawal, Devel Med Child Neurol 49(2007), 626-628.
16. M. Inghilleri, A. Berardelli, P. Marchetti and M. Manfredi, Effects of diazepam, baclofen and thiopental on the silent period evoked by transcranial magnetic stimulation in humans, Exp Brain Res 109(1996), 467-472.
17. H. J. Hachen and V. Krucker, Clinical and Laboratory Assessment of the Eficacy of Baclofen on Urethral Sphincter Spasticity in Patients with Traumatic Paraplegia, Eur Urol 3(1977), 237-240.
18. D. R. Curtis and G. Lacey, Prolonged GABA-B receptormediated synaptic inhibition in the cat spinal cord: an in vivo study, Exp Brain Res 121(1998), 319-333.
19. E. E. M. Weerts, W. Froestl and R. R. Griffiths, Effects of GABAergic modulators on food and cocaine self administration in baboons, Drug Alcohol Depend 80(2005), 369-376.
20. S. R. Platt, S. T. Radaelli and J. J. McDonnell, The Prognostic Value of the Modified Glasgow Coma Scale in Head Trauma in Dogs, J Vet Intern Med 15(2001), 581-584.
21. E. E. Patterson, V. Goel, J. C. Cloyd, T. D. O'Brien, J. E. Fisher, A. W. Dunn et al., Intramuscular, intravenous and oral levetiracetam in dogs: safety and pharmacokinetics, J Vet Pharmacol Therap 31(2008), 253-258.
22. R. Lal, J. Sukbuntherng, E. H. L. Tai, S. Upadhyay, F. Yao, M. S. Warren et al., Arbaclofen Placarbil, a Novel R-Baclofen Prodrug: Improved Absorption, Distribution, Metabolism, and Elimination Properties Compared with R-Baclofen, J Pharmacol Exp Ther 330(3) (2009), 911-921.
23. J. C. Albretson, Oral Medications, Vet Clin Small Anim 32(2002), 421-442.
24. D. V. Hecht and K. Allenspach, Presumptive Baclofen Intoxication in a Dog, Vet Emerg & Crit Care 8(1) (1998), 49-54.
25. B. Pirard, P. Carrupt, B. Testa, R. Tsai, P. Berthelot, C. Vaccher et al., Structure-Affinity Relationships of Baclofen and 3-Hereoaromatic Analogues, Bioorg Med Chem 3(11) (1995), 1537-1545.
26. E. Knutsson, U. Lindblom and A. Martensson, Plasma and cerebrospinal fluid levels of baclofen (Lioresal) at optimal therapeutic responses in spastic paresis, J Neurolog Sci 23(1974), 473-484.
27. H. E. Wiersma, C. J. van Boxtel, J. J. Butter, W. M. C. van Aalderen, T. Omari and M. A. Benninga, Pharmacokinetics of a Single Oral Dose of Baclofen in Pediatric Patients with Gastroesophageal Reflux Disease, Ther Drug Monit 24(1) (2003), 93-98.
28. M. L. Aisen, M. A. Dietz, P. Rossi, J. M. Cedarbaum and H. Kutt, Clinical and Pharmacokinetic Aspects of High Dose Oral Baclofen Therapy, J Am Paraplegia Soc 15(4) (1992), 211-216.
29. M. Podell, Antiepileptic Drug Therapy, Clin Tech Small Animal Prac 13(3) (1998), 185-192.
30. J. W. Faigle and H. Keberle, The chemistry and kinetics of Lioresal, Postgrad Med J 48(Supplement 5) (1972), 9-13.
31. E. W. Wuis, M. J. Dirks, E. F. Termond, T. B. Vree and E. Van der Kleijn, Plasma and urinary excretion kinetics of oral baclofen in health subjects, Eur J Clin Pharmacol 37(2) (1989), 181-184.
32. S. R. Platt, S. C. Randell, K. C. Scott, C. L. Chrisman, R. C. Hill and R. R. Gronwall, Comparison of plasma benzodiazepine concentrations following intranasal and intravenous administration of diazepam to dogs, Am J Vet Res 61(6) (2000), 651-654.
33. C. A. Wunderlich and L. E. Krach, Gram-negative meningitis and infections in individuals treated with intrathecal baclofen: a retrospective study, Dev Med Child Neurol 48(6) (2006), 450-455.